JERUSALEM (Reuters) -Teva Pharmaceutical Industries reported on Wednesday a higher-than-expected rise in third-quarter profit, helped by strong sales of its trio branded drugs to treat migraines, Huntington’s disease and schizophrenia.
Shares in the world’s largest generic drugmaker were up 9.2% by 1230 GMT, against a 0.1% rise in the wider Tel Aviv index.
The company said it earned 78 cents per diluted share, excluding one-time items, in the July to September quarter, up from 69 cents a share a year earlier. Revenue was up 3% in dollar terms at $4.48 billion.
Analysts had forecast earnings of 67 cents per share ex-items for the Israel-based company on revenue of $4.34 billion, LSEG I/B/E/S data showed.
The group revised down its 2025 revenue estimate to $16.8-$17.0 billion from $16.8-$17.2 billion and updated its adjusted EPS forecast to $2.55-$2.65 from $2.50-$2.65.
(Reporting by Steven Scheer; Editing by Jan Harvey)
Comments